MACD Oscillator Analysis for Nektar Therapeutics (NASDAQ:NKTR)


Technical Indicators and Signals

The stochastic oscillator indicator is the important indicator to compare the security price over a certain period of time. The stochastic %K of Nektar Therapeutics (NASDAQ:NKTR) for the period of 9-Day stands at 25.07% while the stochastic %D for the same period stands at 18.53%.

The 7-Day Average Directional Index ADX (also known as Trend Strength Indicator) of Nektar Therapeutics (NASDAQ:NKTR) signals “Buy” while other important signals like the 20-Day Moving Average Vs. Price signals “Buy”.

Another important signal of trend and momentum of a security is 20-50 Day MACD Oscillator or Moving Average Convergence Divergence signals “Buy” for Nektar Therapeutics (NASDAQ:NKTR) while 20-100 Day MACD Oscillator indicates “Buy”.

Bollinger band is a volatility indicator of a certain security, currently Nektar Therapeutics (NASDAQ:NKTR)’s 20-Day Bollinger Band indicates “Hold”.

About Company

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid.  Also in the area of pain, NKTR-181, the company’s wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.

Previous Day Activity Analysis

On the last trading day, Nektar Therapeutics (NASDAQ:NKTR) opened the session at $23.3 and after going up 2.03% closed at $23.67. The stock gained 0.37 points in the last trade.

Nektar Therapeutics (NASDAQ:NKTR)’s stock fluctuated in the range of $23.30 and $24.02 during the previous active session. Nektar Therapeutics (NASDAQ:NKTR) traded with the volume of 1.35 Million with average volume of 1.19 Million. The stock has LOW volatility on the last trading session.

Currently the Beta for the company remains at 1.38 while ATR (Average True Range) and RSI (Relative Strength Index) are at 0.82 and 58.66 respectively.

Currently the Insider Ownership of the shares of Nektar Therapeutics (NASDAQ:NKTR) is at 0.9% and the shares outstanding are 155.12 Million.

Important Ratio Analysis

Some important ratios to consider here for Nektar Therapeutics (NASDAQ:NKTR) are discussed below:

Dividend yield of Nektar Therapeutics (NASDAQ:NKTR) stands at 0% whereas Price to Earnings P/E ratio stands at 0 while Forward P/E shows the value of 0.

The Price to Sale P/S and Price to Book P/B shows the value of 27.59 and 1183.5 respectively. While Price to Cash P/C and Price to Free Cash Flow P/FCF stands at 13.83 and 0 correspondingly.

The Quick Ratio of Nektar Therapeutics (NASDAQ:NKTR) stands at 3.8 while the Current Ratio depicts the value of 4.

Return on Assets ROA of Nektar Therapeutics (NASDAQ:NKTR) is at -41.9% whereas, Return on Equity ROE and Return of Investment ROI of Nektar Therapeutics (NASDAQ:NKTR) stand at 0% and -33.8% respectively.

Stock Performance Analysis

The stock performance of Nektar Therapeutics (NASDAQ:NKTR) on the basis of 5 day trade show the dip of -0.92% whereas, the monthly performance of the stock shows increase of 7.35%.

The quarterly performance of the stock remained in green zone with the value of 9.58% while six month performance of the shares of Nektar Therapeutics (NASDAQ:NKTR) remained bullish with the count of 27.36%.

The yearly and YTD performance of Nektar Therapeutics (NASDAQ:NKTR) remained up at 48.96% and 92.91% respectively.